Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway | Zendy

Jiafeng Tong | Zendy; Ying Shen | Zendy; Zhenghua Zhang | Zendy; Ye Hu | Zendy; Xu Zhang | Zendy; Li Han | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway

Author(s) -

Jiafeng Tong,

Ying Shen,

Zhenghua Zhang,

Ye Hu,

Xu Zhang,

Li Han

Publication year - 2019

Publication title -

bioscience reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.938

H-Index - 77

eISSN - 1573-4935

pISSN - 0144-8463

DOI - 10.1042/bsr20190452

Subject(s) - snail , colorectal cancer , epithelial–mesenchymal transition , metastasis , cancer research , slug , apigenin , cancer , transcription factor , biology , in vivo , signal transduction , medicine , microbiology and biotechnology , gene , biochemistry , genetics , ecology , flavonoid , antioxidant

Colon cancer is a leading cause of cancer-related deaths worldwide. The epithelial-mesenchymal transition (EMT) plays an important role in tumor metastasis of colon cancer. We first evaluated the effects of EMT-related transcription factors on the prognosis of colon cancer through analysis the data obtained from The Cancer Genome Atlas (TCGA). And then we screened a series of Chinese medicine monomers to find effect EMT inhibitors. First, Snail is a more important EMT transcription factors for colon cancer prognosis, compared with Twist and Slug. Then, we found that apigenin effectively inhibits the activity of Snail. Apigenin could inhibit the EMT, migration, and invasion of human colon cancer cells in vitro and in vivo through the NF-κB/Snail pathway. Snail is a key regulator of EMT in colon cancer and Snail inhibitor apigenin may be a therapeutic application for patients with colon cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research